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Tumor suppressors are frequently downregulated in human cancers and understanding of the mechanisms through
which tumor cells restrict the expression of tumor suppressors is important for the prognosis and intervention of
diseases. The promyelocytic leukemia (PML) protein plays a critical role in multiple tumor suppressive functions,
such as growth inhibition, apoptosis, replicative senescence, suppression of oncogenic transformation, and
inhibition of migration and angiogenesis. These tumor suppression functions are recapitulated in several mouse
models. The expression of PML protein is frequently downregulated in diverse types of human tumors and this
downregulation often correlates with tumor progression. Recent evidence has emerged that PML is aberrantly
degraded in various types of tumors through ubiquitination-dependent mechanisms. Here, we summarize our
current understanding of the PML ubiquitination/degradation pathways in human cancers. We point out that
multiple pathways lead to PML ubiquitination and degradation. Furthermore, the PML ubiquitination processes are
often dependent on other types of posttranslational modifications, such as phosphorylation, prolylisomerization,
and sumoylation. Such feature indicates a highly regulated nature of PML ubiquitination in different cellular
conditions and cell contexts, thus providing many avenues of opportunity to intervene PML ubiquitination
pathways. We discuss the potential of targeting PML ubiquitination pathways for anti-cancer therapeutic strategies.
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Introduction
The PML gene was originally identified at the breakpoint
of the t(15;17) chromosomal translocation that is found
in most cases of acute promyelocytic leukemia (APL)
[1]. This translocation generates PML-RARα fusion pro-
tein, which plays a driving role in APL pathogenesis.
Since its discovery, the PML gene has been subject to in-
tensive studies. The human PML gene can give rise to at
least 12 transcripts due to alternative splicing [2,3].
These isoforms share an identical N-terminal region
containing RBCC (Ring, B-box, and coiled-coil) motif
but differ in their C-termini. PML is the essential com-
ponent of PML-nuclear bodies (PML-NBs), which are
spherical subnuclear organelles with a diameter of 0.1 to
1 μm [4,5]. PML functions as the organizing center of
this structure, allowing the recruitment of numerous* Correspondence: rhchen@gate.sinica.edu.tw
1Institute of Biological Chemistry, Academia Sinica, Taipei, Taiwan
2Institute of Biochemical Sciences, College of Life Science, National Taiwan
University, Taipei, Taiwan
© 2012 Chen et al.; licensee BioMed Central L
Commons Attribution License (http://creativec
reproduction in any medium, provided the orproteins through mechanisms involving SUMO-
modifications and interactions [6]. PML-NBs are known
to fine tune a number of cellular processes and most of
them are related to tumor suppression [4]. As PML is
crucial for the assembly of PML-NBs, the biological
functions of PML-NBs are somewhat difficult to be dis-
tinguished from those of PML.PML tumor suppressive functions
The tumor suppressive function of PML was first sug-
gested by the identification of PML-RARα fusion protein
in APL. Additional genetic evidence comes from PML
null mice. These mice are prone to develop papilloma,
carcinoma, and T/B lymphomas in several chemical and
physical modes of carcinogenesis [7]. When crossed with
other tumor mouse models, PML loss accelerates tumor
development [8]. Furthermore, studies with in vitro and/
or in vivo systems have revealed a number of PML-
elicited cellular functions that are related to tumor sup-
pression. These functions are described below:td. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
Chen et al. Journal of Biomedical Science 2012, 19:81 Page 2 of 7
http://www.jbiomedsci.com/content/19/1/811. Regulation of apoptosis: Many lines of evidence
indicate a role of PML in modulating apoptosis. For
instance, lymphocytes, thymocytes and embryonic
fibroblasts derived from PML−/− mice are more
resistant to apoptosis induced by stimuli that activate
either intrinsic or extrinsic apoptotic pathway,
compared with their wild type counterparts [9,10].
The pro-apoptotic functions of PML can be mediated
by both p53-dependent and p53-independent
mechanisms. PML activates p53 by multiple
mechanisms, such as promoting its phosphorylation
and acetylation by recruiting it into PML-NBs and by
binding and inhibiting the p53 negative regulator
MDM2 [11,12]. Besides p53, several other factors are
implicated in the pro-apoptotic function of PML. One
such molecule is Daxx, which is recruited to PML-
NBs through its interaction with sumoylated PML
[13]. Daxx is reported to repress the expression of
several anti-apoptotic genes when localized in PML-
NBs, thereby eliciting pro-apoptotic functions [14].
Recently, the extranuclear PML has been reported to
form a complex with inositol 1,4,5-triphosphate
receptor (IP3R), Akt and PP2a in ER and
mitochondria-associated membrane, where PML
participates in Akt- and PP2a-dependent modulation
of IP3R phosphorylation to promote IP3R-mediated
calcium release from ER, thereby inducing apoptosis
[15].
2. Regulation of cellular senescence: PML was first
implicated in cellular senescence by its requirement
for V-H-Ras-induced senescence via modulating p53
acetylation and activation [16]. Subsequently, it has
been found that overexpression of a particular PML
isoform, PML-IV, induces senescence through an
Rb-dependent mechanism [17,18]. Intriguingly,
during the induction of senescence, PML-NBs are
colocalized with senescence-associated
heterochromatin foci (SAHF), Rb, and E2F, which is
thought to mediate PML-induced repression of E2F
target genes, leading to proliferation arrest, DNA
damage and senescence [19]. Recent study identified
TBX2, a T-box transcription factor, as an E2F target
critical for PML-induced senescence [20].
3. Regulation of neoangiogenesis: PML deficiency leads
to increased neoangiogenesis and elevated
expression of pro-angiogenic factors such as HIF-1α
and VEGF in human and mouse tumors. PML
inhibits angiogenesis by negatively regulating the
Akt-mTOR pathway, which controls the protein
synthesis of HIF-1α. PML can recruit PP2a to PML-
NBs, thereby dephosphorylating and inactivating
Akt [21]. In addition, PML recruits mTOR activator
Rheb to the nucleus, thereby inhibiting mTOR [22].
The ability of PML to regulate mTOR/HIF-1αpathway also implicates its function in hypoxia
responses.
4. Regulation of cell migration: PML was recently
found to inhibit the migration of MDA-MB231
breast cancer cell lines by downregulating the
expression of integrin β1. This finding also
implicates a role of PML in suppressing tumor
metastasis [23].
5. Regulation of DNA damage responses: PML has been
implicated in regulating DNA damage responses by
targeting a number of effectors of these pathways to
PML-NBs [24]. In response to DNA damage, the
number and size of PML-NBs are increased in an
ATM- and ATR-dependent manner [25]. However,
the functional consequence of this phenomenon is
currently unknown.
Regulation of PML expression in human cancers
The pleiotropic functions of PML in tumor suppression
suggest that inactivation or downregulation of PML would
provide an advantage for tumor development and progres-
sion. Indeed, in addition to the disruption of PML func-
tion by PML-RARα fusion protein in APL, complete or
partial loss of PML protein expression has been observed
in human cancers from multiple origins, such as prostate
adenocarcinoma, colon adenocarcinoma, breast carcin-
oma, lung carcinoma, lymphoma, CNS tumors, and germ
cell tumors. In certain types of tumors, such as prostate
cancer, PML loss correlates with invasive and metastatic
progression. Interestingly, despite the frequent downregu-
lation of PML protein in tumors, PML mRNA is
expressed in all tumor samples and cell lines tested. This
study further showed that treatment of several PML-
negative tumor cell lines with proteasome inhibitor leads
to re-expression of PML protein and restoration of PML-
NBs [26]. Thus, proteasome-dependent degradation is
proposed to be a mechanism by which tumor cells restrict
the expression of PML. Since ubiquitination is the major
posttranslational modification that controls protein deg-
radation through proteasome, identification of PML ubi-
quitin ligases would provide insights into the mechanism
of PML regulation in human cancers.
RNF4-mediated PML ubiquitination
Arsenic trioxide (ATO) is the leading choice of anti-APL
therapeutic agent [27]. Mechanistically, ATO triggers
PML-RARα degradation through its PML moiety and
sumoylation at K160 residue is necessary for targeting
PML-RARα and PML to the proteasome [28]. Interest-
ingly, ATO directly binds to several adjacently localized
cysteine residues in the PML RING domain to facilitate
PML oligomerization [29]. In addition, ATO-induced ROS
production also contributes to PML intermolecular cross
linking by disulfide bonds [30]. Oligomerization of PML
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interaction with SUMO conjugating enzyme Ubc9, thus
facilitating PML hypersumoylation [29]. A recent study
indicates an involvement of SUMO E3 ligase PIAS1 in
ATO-triggered PML sumoylation [31]. The molecular
mechanism governs sumoylation-induced PML ubiqui-
tination has been elucidated. A family of SUMO tar-
geted ubiquitin ligases (STUbLs) was discovered by
their harboring of a RING domain and multiple
SUMO-interacting motifs (SIMs). This structure feature
allows STUbLs to specifically recognize sumoylated
substrates [32]. RNF4 is a STUbL-family E3 ligase and
is rapidly recruited to PML-NBs following ATO treat-
ment through a SUMO-dependent mechanism [33].
With its multiple SIMs, RNF4 interacts strongly with
polysumoylated PML, thereby facilitating PML K48
poly-ubiquitination and proteasomal degradation
[34,35]. RNF4 depletion leads to accumulation of poly-
sumoylated PML and impairment of ATO-triggered
PML degradation. Among the three sumoylation resi-
dues of PML, K160 is most critical for RNF4
recruitment and ATO-induced proteolysis [35]. This
SUMO-coupled ubiquitination mechanism also applies
to PML-RARα. Accordingly, primary haematopoietic
cells transformed by K160 mutant of PML-RARα are
resistant to ATO-induced terminal differentiation.
Dominant-negative RNF4 similarly blocks this ATO-
induced differentiation. Thus, RNF4-mediated PML-RARα
ubiquitination and degradation plays a vital role in the
APL therapeutic response to ATO.
KLHL20-mediated PML ubiquitination
KLHL20 is a member of the BTB-kelch family proteins.
Similar to many members of this family, KLHL20
forms a ubiquitin E3 ligase complex with Cullin3 and
Roc1 and functions as the substrate binding compo-
nent of this ligase. The first linkage between KLHL20
and PML is the observation that a small fraction of
KLHL20 is distributed to PML-NBs under normal
growth conditions. This distribution is further aug-
mented with the increase of PML transcription by
interferon [36]. The expression of KLHL20 is induced
under hypoxia conditions through a HIF-1-dependent
manner and this KLHL20 induction correlates with
downregulation of PML protein expression. Subse-
quent study indicates that the KLHL20-based E3 ligase
complex mediates hypoxia-induced PML ubiquitina-
tion and proteolysis. However, targeting PML to
KLHL20 requires two posttranslational modifications.
The first one involves phosphorylation of PML at S518
by CDK1 and CDK2. The S518-phosphorylated PML is
then recognized by peptidylprolyl cis/trans isomerase
Pin1 and Pin1-catalyzed isomerization further potenti-
ates PML interaction with KLHL20. Importantly, thishypoxia-induced, KLHL20-mediated PML ubiquitina-
tion pathway not only attenuates PML tumor suppressive
functions but also participates in a feedback mechanism
to maximize the production of HIF-1α during hypoxic
stress. Consequently, KLHL20-PML pathway amplifies
multiple tumor hypoxia responses, such as metabolic re-
programming, epithelial-mesenchymal transition, migra-
tion, tumor growth, angiogenesis, and chemoresistance,
and these functions collectively lead to aggressive tumor
phenotypes. Clinically, overexpression of HIF-1α,
KLHL20, Pin1 and downregulation of PML are found in
prostate cancers. While the expression of HIF-1α posi-
tively correlates with that of KLHL20, PML expression in-
versely correlates with the expression of HIF-1α, KLHL20
and Pin1. More importantly, the HIF-1α high, KLHL20
high, Pin1 high and PML low expression profile correlates
with high-grade tumors. These clinical data strongly sug-
gest the existence of this PML destruction pathway in
prostate cancer and the association of its hyperactivation
with disease progression [37]. Thus, the Roc1-Cullin3-
KLHL20 complex represents the first PML ubiquitin ligase
that is dysregulated in human cancers and the KLHL20-
mediated PML destruction and HIF-1α feedback regula-
tion contribute significantly to tumor progression.
E6AP-mediated PML ubiquitination
E6AP is the founding member of the HECT-family ubi-
quitin ligases [38], in which ubiquitin is covalently
bound to the HECT domain before transferring to sub-
strates [39]. E6AP is partially localized in PML-NBs
and is physically associated with PML. Consistent with
these features, E6AP promotes ubiquitination and pro-
teasomal degradation of PML. The physiological role
of E6AP in PML degradation is highlighted by the find-
ing that multiple organs of E6AP null mice display ele-
vated PML protein level. The increased level of PML
protein and PML-NBs are also evident from E6AP-
deficient mouse embryonic fibroblasts. Furthermore,
lymphoid cells derived from such mice accumulate PML
protein in response to DNA damage and are more suscep-
tible to DNA damage-induced death, implying a role of
this PML degradation in cell response to genotoxic stress
[40]. More direct evidence for the function of E6AP-
mediated PML degradation in tumorigenesis comes from
the study of Myc-induced B-cell lymphomagenesis. The
Eμ-myc transgenic mice represent a well established
model for pre-B/B lymphoma development [41,42]. Im-
portantly, loss of one allele of E6AP delays the onset of
Myc-induced pre-B/B cell lymphoma and reduces the
tumor burden. Mechanistically, the suppression of lym-
phomagenesis by E6AP heterozygosity is attributed to the
increased senescence of pre-B/B lymphoma cells, as evi-
dent by the elevated expression of senescence markers
SA-β-Gal, p16, p21 and SAHF marker H3K9me3.
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lymphoma cells and premalignant B-lymphoid cells
derived from Eμ-myc/E6AP+/− mice exhibit elevated
levels of PML and PML-NBs compared with those cells
derived from Eμ-myc mice. Importantly, loss of one or
both allele of PML significantly accelerates lymphoma
development in Eμ-myc mice model, supporting the
contribution of PML elevation to the suppression of
lymphomagenesis observed in Eμ-myc/E6AP+/− mice.
Clinically, elevated E6AP expression is observed in
human Burkitt lymphoma specimens and a number of
B lymphoma cell lines and this elevated E6AP expres-
sion is associated with PML downregulation [43].
Thus, E6AP-mediated PML ubiquitination and degrad-
ation potentiates lymphomagenesis by inhibition of cell
senescence and elevated E6AP expression likely contri-
butes in part to PML downregulation in B cell
lymphomas.
Casein kinase 2 (CK2)-dependent PML ubiquitination
Besides CDK1/2, other kinases can also influence on
PML ubiquitination and proteasomal degradation. One
such kinase is CK2, a serine/threonine kinase with onco-
genic potential [44]. CK2 phosphorylates PML at mul-
tiple sites. Among them, S517 (S565 in PML-I) is the
prime phosphorylation residue and is within a PML
degron. CK2 is known to be activated by p38MAPK dur-
ing cell stress. In line with a role of CK2 in PML degrad-
ation, several stress conditions that activate CK2, such
as osmotic shock and UV irradiation, potentiates PML
proteasomal degradation. Inhibition of either p38MAPK
or CK2 abrogates stress-induced PML degradation. Fur-
thermore, PML ubiquitination is stimulated by a CK2-
activating signal (i.e., osmotic shock) or by introducing a
PML mutant that mimics the CK2 phosphorylation
event [8]. These observations lead to the hypothesis that
CK2 phosphorylation primes PML ubiquitination via an
unidentified ubiquitin ligase. Interestingly, the CK2
phosphorylation residues are within an extended SIM
and phosphorylation of these residues affects PML bind-
ing to sumoylated proteins [45,46]. The significance of
CK2-dependent PML degradation in cancer biology is
highlighted by the finding that PML phosphomimetic
mutant acts as a super tumor suppressor due to its pro-
longed half-life. This mutant induces stronger senes-
cence and apoptotic effects in cell-based assays and a
more potent tumor suppressive function in a xenograft
model, compared with wild type PML. In human can-
cers, aberrant activation of CK2 is found in a subset of
non-small cell lung cancer (NSCLC) cell lines and pa-
tient specimens, which correlates with decreased PML
protein levels [8,47]. Thus, the CK2-dependent PML
degradation pathway is likely dysregulated in NSCLC to
influence on tumor development and progression.ERK2-dependent PML proteasomal degradation
ERK2 is another PML kinase that stimulates PML pro-
teasomal degradation. ERK2 is partially localized in
PML-NBs and phosphorylates PML at S403 and S505
[48]. Similar to CDK1/2-induced PML phosphorylation,
phosphorylation of PML by ERK2 facilitates the recruit-
ment of Pin1, which promotes PML proteasomal deg-
radation [49]. As protein degradation through
proteasome is mainly mediated by ubiquitination, the
ERK2- and Pin1-modified PML likely recruits an un-
identified E3 ligase for its ubiquitination. ERK2 activity
is stimulated by multiple growth factors, including EGF.
Accordingly, EGF increases PML degradation through
ERK2- and Pin1- dependent manner [48]. Given a fre-
quent ERK2 activation in various types of human can-
cers, the ERK2/PML axis may contribute to PML
degradation in certain cancers.
Targeting PML ubiquitination pathway as anti-cancer
strategies
In viewing of the pleiotropic functions of PML in
tumor suppression and its frequent degradation in
various types of cancers, targeting the PML ubiquitina-
tion/degradation pathway becomes an attractive ap-
proach for anti-cancer therapy. In theory, several
approaches can be used for screening small molecular
inhibitors that blocks PML ubiquitination pathways.
The first one is to target the ubiquitin E3 ligases. Of
note, a number of high throughput screening methods
have been established for identifying inhibitors of E3
ligases [50]. For multi-subunit E3 ligases, the screen
strategy can be designed for the disruption of inter-
action between subunits. The second approach is to
screen small molecular inhibitors that disrupt the
interaction of PML with its E3 ligases. Finally, since
PML posttranslational modifications, such as phos-
phorylation and sumoylation, are often required for
the subsequent ubiquitination events, targeting such
posttranslational modification processes (e.g., by intro-
ducing a kinase inhibitor) can also prevent PML ubi-
quitination. In line with this notion, CK2 inhibitor
emodin suppresses tumor growth in a xenograft model
and this effect depends on the presence of a CK2 phos-
phorylation residue on PML [8]. The Cullin-family E3
ligase inhibitor MLN4924, which inhibits Cullin ned-
dylation by targeting NEDD8 activating enzyme, elicits
profound anti-tumor effects [51]. It would be intri-
guing to test whether MLN4924 attenuates prostate
cancer progression induced by KLHL20-mediated PML
degradation. Importantly, recent evidence has emerged
that multiple pathways govern PML degradation in
tumors and different types of cancers likely use distinct
mechanisms to regulate PML stability. Thus, a full
understanding of PML ubiquitination mechanisms in
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aid in the design and selection of specific anti-cancer
strategies for treating cancer patients displaying aber-
rant PML degradation.Conclusions
The ubiquitin-proteasome system plays a key role in
maintaining cellular homeostasis and aberrant
ubiquitin-dependent degradation of tumor suppressor
proteins contributes to human tumorigenesis. The
PML tumor suppressor protein is frequently downre-
gulated in human cancers through a proteasome-
dependent mechanism. Recent studies have revealed
multiple pathways that lead to PML ubiquitination and
degradation. These pathways involve distinct ubiquitin
ligases and are often primed by different PMLFigure 1 Summary of the PML ubiquitination/degradation pathways.
primed by distinct PML posttranslational modifications, mediated by indica
Unidentified E3 ligases are shown by question marks.posttranslational modifications. Thus, it is conceivable
that each PML ubiquitination pathway is stimulated
under distinct cellular conditions, such as hypoxia,
ROS, growth factors, and cell stress (Figure 1). Al-
though aberrant regulation of some of these PML ubi-
quitination pathways has been observed in certain
types of cancers, the prevalent PML degradation in
cancers suggest the existence of additional ubiquitina-
tion pathways and/or regulatory mechanisms. Further-
more, the mechanism of PML deubiquitination, a
process opposing ubiquitination, remains unexplored.
It is important to further elucidate the regulatory
mechanisms of PML ubiquitination in human cancers.
As our understanding of this event progresses, more
specific inhibitors targeting a particular pathway will
be discovered to antagonize a particular subset of
human cancers displaying aberrant PML degradation.These pathways are activated by extracellular or intracellular stimuli,
ted E3 ligases, and perturbed in different types of human cancers.
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